PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
11.79%
Revenue growth under 50% of CRON.TO's 23.88%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
-46.43%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-309.91%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-309.91%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-2284.85%
Negative net income growth while CRON.TO stands at 135.37%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-2260.25%
Negative EPS growth while CRON.TO is at 134.09%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-2260.25%
Negative diluted EPS growth while CRON.TO is at 134.09%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.61%
Share reduction more than 1.5x CRON.TO's 2.40%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.61%
Diluted share reduction more than 1.5x CRON.TO's 2.40%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
104.19%
OCF growth above 1.5x CRON.TO's 12.62%. David Dodd would confirm a clear edge in underlying cash generation.
80.26%
FCF growth above 1.5x CRON.TO's 20.28%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
946.12%
5Y CAGR of 946.12% while CRON.TO is zero. Bruce Berkowitz would see if small improvements can scale into a larger advantage.
538.59%
3Y revenue/share CAGR above 1.5x CRON.TO's 185.86%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-84.89%
Negative 10Y OCF/share CAGR while CRON.TO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
65.84%
Positive OCF/share growth while CRON.TO is negative. John Neff might see a comparative advantage in operational cash viability.
261.74%
Positive 3Y OCF/share CAGR while CRON.TO is negative. John Neff might see a big short-term edge in operational efficiency.
-5501.82%
Negative 10Y net income/share CAGR while CRON.TO is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-4443.43%
Negative 5Y net income/share CAGR while CRON.TO is 565.25%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-289.78%
Negative 3Y CAGR while CRON.TO is 4800.85%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
3122.11%
Equity/share CAGR of 3122.11% while CRON.TO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
403.50%
Below 50% of CRON.TO's 1504.53%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-8.22%
Negative 3Y equity/share growth while CRON.TO is at 346.15%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.56%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
2.73%
We show growth while CRON.TO is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
13.71%
Positive asset growth while CRON.TO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
5.38%
BV/share growth above 1.5x CRON.TO's 1.50%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
29.90%
We have some new debt while CRON.TO reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
88.66%
R&D growth drastically higher vs. CRON.TO's 1.90%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
18.88%
SG&A growth well above CRON.TO's 10.19%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.